Today: 11 June 2026
Lam Research stock slips 3% after fresh high as Citi, Deutsche Bank lift targets into earnings
23 January 2026
1 min read

Lam Research stock slips 3% after fresh high as Citi, Deutsche Bank lift targets into earnings

New York, Jan 22, 2026, 17:42 EST — After-hours

  • Lam Research shares dipped Thursday, retreating from the 52-week peak they hit just the day before
  • Ahead of Lam’s Jan. 28 quarterly earnings, Citi and Deutsche Bank both bumped up their price targets this week
  • Traders are focusing on chip-equipment spending forecasts for 2026, not just this quarter’s figures

Shares of Lam Research Corp fell 3.4% Thursday, closing at $220.70. During the day, the stock fluctuated between $238.20 and $219.39, and it held close to the closing price in after-hours trading.

The drop comes just a week ahead of Lam’s December-quarter earnings release on Jan. 28. Investors will focus on what management reveals about customer spending outlook for 2026, particularly around memory and advanced logic chips.

Citigroup boosted its price target for Lam to $265 from $190, maintaining a Buy rating. The firm described Lam as being in a “Phase 2 upcycle,” driven by wafer fab equipment spending edging closer to Citi’s bullish forecast. TipRanks

Deutsche Bank’s Melissa Weathers bumped her price target on Lam to $260 from $195, maintaining a Buy rating. She anticipates the company will deliver results “solidly above Street” expectations shortly. TipRanks

Lam took a notable hit on a day when U.S. stocks mostly rose—the S&P 500 gained 0.6%—yet the chip-equipment firm ended roughly 5% below its 52-week peak of $232.90, reached just Wednesday. Applied Materials slid around 2% during the session. Lam’s trading volume hovered near its recent average, according to MarketWatch data.

This group’s back-and-forth is nothing new. Targets jump up fast when analysts raise them, but then stocks swing wildly over minor details — order timing, who the customers are, or any sign that robust spending might be slowing down.

Lam supplies tools that deposit and etch thin layers on wafers. Demand usually tracks major capital spending at chipmakers, so the outlook commentary matters as much as the quarter’s revenue and profit.

The setup works two ways. A slip in customer capex or stricter export controls limiting shipments to China could disrupt forecasts — a risk peers have flagged as Washington ramps up restrictions.

Investors are keen on Lam’s take on backlog and shipments, plus how much of 2026 spending is just being pulled forward rather than actually growing. Margin discussions will be crucial, particularly if the more expensive tools and services are carrying a bigger load.

Lam’s earnings report and conference call are set for Jan. 28. Investors will zero in on the forward guidance, which will probably drive the initial market response more than the headline figures.

Stock Market Today

  • What is an IPO as SpaceX Prepares for U.S. Stock Market Debut
    June 10, 2026, 6:01 PM EDT. An IPO, or Initial Public Offering, is when a private company sells shares to the public for the first time, becoming publicly traded. SpaceX, the aerospace manufacturer, is expected to make its debut on the U.S. stock market, marking one of the most anticipated IPOs in recent years. This move allows retail and institutional investors to buy equity in SpaceX, potentially impacting the space industry and tech sectors. The IPO process involves regulatory filings, pricing, and public trading, providing companies with capital for expansion. SpaceX's offering could reshape market dynamics, drawing significant investor interest given its innovations and growth trajectory.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud
Previous Story

Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Next Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Go toTop